| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.0M | — | -12.3% |
| SG&A Expense | $2.8M | — | -6.3% |
| Operating Income | -$5.8M | — | +9.5% |
| Net Income | -$5.7M | — | +14.4% |
| EPS (Basic) | -$1.33 | — | -850.0% |
| EPS (Diluted) | -$1.33 | — | -850.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $8.3M | -36.7% | -40.0% |
| Current Assets | $9.3M | -34.0% | -37.8% |
| Total Assets | $11.1M | -25.8% | -30.7% |
| Current Liabilities | $4.9M | +2.6% | -19.0% |
| Total Liabilities | $6.4M | +26.6% | -0.1% |
| Stockholders' Equity | $3.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.8M | — | +48.4% |
| Capital Expenditures | $3K | — | — |
| Investing Cash Flow | -$3K | — | — |
| Free Cash Flow | -$4.8M | — | — |
| -59.6% |